Allergic Rhinitis Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Iltoo Pharma, Revolo Biotherapeutics

August 31 22:32 2023
Allergic Rhinitis Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Iltoo Pharma, Revolo Biotherapeutics
(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Allergic Rhinitis pipeline constitutes 35+ key companies continuously working towards developing 35+ Allergic Rhinitis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Allergic Rhinitis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details. 

 

Allergic Rhinitis Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Allergic Rhinitis Market.

 

Some of the key takeaways from the Allergic Rhinitis Pipeline Report:

  • Companies across the globe are diligently working toward developing novel Allergic Rhinitis treatment therapies with a considerable amount of success over the years. 
  • Allergic Rhinitis companies working in the treatment market are Funpep, Inimmune, Chia Tai Tianqing Pharma, Iltoo Pharma, Revolo Biotherapeutics, Anhui Palo Alto Pharma, Immunotek SL, Abdi Ibrahim Pharma, Regeneron Pharma, Allergy Therapeutics, Advagene Biopharma, and others, are developing therapies for the Allergic Rhinitis treatment 
  • Emerging Allergic Rhinitis therapies in the different phases of clinical trials are- FPP004, INI 2004, TQC 3564, ILT-101, IRL201104, PA9159, MM09-MG01, AI201901, REGN5713-5714-5715, MPL allergy vaccine, AD 17002, and others are expected to have a significant impact on the Allergic Rhinitis market in the coming years.   
  • In January 2022, Glenmark made a statement approving Ryaltris. The FDA has approved Ryaltris, a metered, fixed-dose, aqueous suspension prescription medication nasal spray, for the treatment of seasonal allergic rhinitis symptoms in adults and children 12 years of age and older. Glenmark and Lotus International, a wholly owned subsidiary of Lotus Pharmaceutical, agreed into a licencing arrangement in January 2022 for the purpose of commercialising Ryaltris, a ground-breaking nasal spray, in Singapore, Hong Kong, and Vietnam.
  • In January 2022, In order to assess the potential effectiveness of REVTx-99 in treating patients with allergic rhinitis and patients with persistent nasal congestion without polyps, Revelation Biosciences dosed and recruited the first patient in a Phase Ib clinical research. Australia is where the clinical investigation is being carried out.
  • Pentosan Polysulfate Sodium (PPS) application in treating the wide range of illnesses that start with and are sustained by inflammation remains Paradigm Pharmaceuticals’ core emphasis. The business is researching the effectiveness of PPS for treating chronic heart failure (CHF), alphavirus-induced arthralgia (in Ross River Virus and Chikungunya patients), and allergic respiratory disorders such allergy rhinitis (AR) and chronic obstructive pulmonary disease (COPD).
  • In May 2022, The Fremont, California-based company BioKey, a wholly-owned subsidiary of ABVC Biopharma, announced that it had signed a $3 million clinical services agreement with NeuCen BioMed Co. Ltd. to oversee the completion of two NeuCen drug products, CEN501 and NEU001, through Phase II clinical studies in accordance with US FDA IND regulatory requirements. Patients with allergic rhinitis caused by mites might utilise CEN501, a nasal strip medication, as local nasal immunotherapy (LNIT).
  • In March 2022, The patient recruitment in Altamira Therapeutics’ Bentrio study for allergic rhinitis caused by house dust mites (“HDM”) has been completed. Top-line trial findings are anticipated to be made public by the company in the second quarter of 2022.
  • In April 2021, Collaboration between Inmunotek S.L., BioClever 2005 S.L., and NTS hub S.In order to compare the effectiveness and safety of subcutaneous immunotherapy using a combination of grasses and mites at sufficient doses with monotherapy, Lini conducted a prospective, randomised, placebo-controlled, multi-center experiment.

 

Allergic Rhinitis Overview

Atopic disease allergic rhinitis (AR) manifests as sneezing, nasal congestion, clear rhinorrhea, and nasal pruritis. A leukotriene-mediated late phase follows an initial IgE-mediated immune response that is directed against inhaled antigens.

 

Get a Free Sample PDF Report to know more about Allergic Rhinitis Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/allergic-rhinitis-pipeline-insight

 

Emerging Allergic Rhinitis Drugs Under Different Phases of Clinical Development Include:

  • FPP004: Funpep
  • INI 2004: Inimmune
  • TQC 3564: Chia Tai Tianqing Pharmaceutical Group
  • ILT-101: Iltoo Pharma
  • IRL201104: Revolo Biotherapeutics
  • PA9159: Anhui Palo Alto Pharmaceuticals
  • MM09-MG01: Immunotek SL
  • AI201901: Abdi Ibrahim Pharmaceuticals
  • REGN5713-5714-5715: Regeneron Pharma
  • MPL allergy vaccine: Allergy Therapeutics
  • AD 17002: Advagene Biopharma

 

Allergic Rhinitis Route of Administration

Allergic Rhinitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical
  • Molecule Type

 

Allergic Rhinitis Molecule Type

Allergic Rhinitis Products have been categorized under various Molecule types, such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Allergic Rhinitis Pipeline Therapeutics Assessment

  • Allergic Rhinitis Assessment by Product Type
  • Allergic Rhinitis By Stage and Product Type
  • Allergic Rhinitis Assessment by Route of Administration
  • Allergic Rhinitis By Stage and Route of Administration
  • Allergic Rhinitis Assessment by Molecule Type
  • Allergic Rhinitis by Stage and Molecule Type

 

DelveInsight’s Allergic Rhinitis Report covers around 35+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Further Allergic Rhinitis product details are provided in the report. Download the Allergic Rhinitis pipeline report to learn more about the emerging Allergic Rhinitis therapies

 

Some of the key companies in the Allergic Rhinitis Therapeutics Market include:

Key companies developing therapies for Allergic Rhinitis are – Abdi Ibrahim Pharmaceuticals, Regeneron Pharmaceuticals, Hanmi Pharmaceutical, Immunotek, Anhui Palo Alto Pharmaceuticals Inc., Revolo Biotherapeutics, Emergo Therapeutics, Advagene Biopharma, AOBiome LLC, CSPC ZhongQi Pharmaceutical, Inimmune, Allergy Therapeutics, Siolta Therapeutics, Worg Pharmaceuticals, ABVC Biopharma, Revelation Biosciences,  Altamira Therapeutics, Qyuns Therapeutics, Dobecure, Funpep, GL Pharm Tech, Archivel Farma, Nasus Pharma, RIKEN, Paradigm Pharmaceuticals,  DC4U, United Biomedical, Marinomed Biotech, Desentum,  Roxall Medizin and others.

 

Allergic Rhinitis Pipeline Analysis:

The Allergic Rhinitis pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of Allergic Rhinitis with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Allergic Rhinitis Treatment.
  • Allergic Rhinitis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Allergic Rhinitis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Allergic Rhinitis market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Download Sample PDF Report to know more about Allergic Rhinitis drugs and therapies

 

Allergic Rhinitis Pipeline Market Drivers

  • Increase in the prevalence of various form of allergic rhinitis, surge in the demand for effective and potent drugs among consumers across the globe are some of the important factors that are fueling the Allergic Rhinitis Market.

 

Allergic Rhinitis Pipeline Market Barriers

  • However, high competition from generic drugs, side-effects associated with the allergic rhinitis treatment and other factors are creating obstacles in the Allergic Rhinitis Market growth.

 

Scope of Allergic Rhinitis Pipeline Drug Insight    

  • Coverage: Global
  • Key Allergic Rhinitis Companies: Funpep, Inimmune, Chia Tai Tianqing Pharma, Iltoo Pharma, Revolo Biotherapeutics, Anhui Palo Alto Pharma, Immunotek SL, Abdi Ibrahim Pharma, Regeneron Pharma, Allergy Therapeutics, Advagene Biopharma, and others
  • Key Allergic Rhinitis Therapies: FPP004, INI 2004, TQC 3564, ILT-101, IRL201104, PA9159, MM09-MG01, AI201901, REGN5713-5714-5715, MPL allergy vaccine, AD 17002, and others
  • Allergic Rhinitis Therapeutic Assessment: Allergic Rhinitis current marketed and Allergic Rhinitis emerging therapies
  • Allergic Rhinitis Market Dynamics: Allergic Rhinitis market drivers and Allergic Rhinitis market barriers 

 

Request for Sample PDF Report for Allergic Rhinitis Pipeline Assessment and clinical trials

 

Table of Contents 

1. Allergic Rhinitis Report Introduction

2. Allergic Rhinitis Executive Summary

3. Allergic Rhinitis Overview

4. Allergic Rhinitis- Analytical Perspective In-depth Commercial Assessment

5. Allergic Rhinitis Pipeline Therapeutics

6. Allergic Rhinitis Late Stage Products (Phase II/III)

7. Allergic Rhinitis Mid Stage Products (Phase II)

8. Allergic Rhinitis Early Stage Products (Phase I)

9. Allergic Rhinitis Preclinical Stage Products

10. Allergic Rhinitis Therapeutics Assessment

11. Allergic Rhinitis Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Allergic Rhinitis Key Companies

14. Allergic Rhinitis Key Products

15. Allergic Rhinitis Unmet Needs

16 . Allergic Rhinitis Market Drivers and Barriers

17. Allergic Rhinitis Future Perspectives and Conclusion

18. Allergic Rhinitis Analyst Views

19. Appendix

20. About DelveInsight

 

About DelveInsight

 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services